HB 1741
In CommitteeHouse
PANDAS, pediatric treatment
Expanding access to treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires private health insurers in Washington to cover intravenous immunoglobulin (IVIG) therapy for children and adolescents with PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) or PANS (Pediatric Acute-onset Neuropsychiatric Syndrome), but only after other treatments have failed or been tolerated. It also requires specialist input and ongoing evaluations to continue coverage.
- Requires health insurers (excluding public employee plans) to cover three initial monthly courses of intravenous immunoglobulin (IVIG) therapy for PANDAS/PANS starting January 1, 2026.
- Allows coverage of additional IVIG courses if deemed medically necessary by the treating provider after initial treatment.
- Requires that patients first try and fail or cannot tolerate two or more less-intensive treatments (e.g., antibiotics, cognitive behavioral therapy) before qualifying for IVIG.
- Mandates consultation with a pediatric subspecialist (or adult subspecialist for older patients), who must jointly recommend the treatment with the patient’s primary care provider; telehealth consultations are allowed.
- Permits insurers to require clinical reevaluation every three months to continue coverage.
Who is affected
- Children and adolescents with PANDAS or PANS — Children and adolescents diagnosed with PANDAS or PANS who require specialized treatment, especially those who have not responded to first-line therapies like antibiotics or cognitive behavioral therapy.
- Families of children with PANDAS/PANS — Families of affected youth who may face high out-of-pocket costs for immunomodulatory treatments like IVIG without insurance coverage.
- Pediatric and adult subspecialists — Pediatric neurologists, psychiatrists, and other subspecialists who treat PANDAS/PANS and must evaluate medical necessity and coordinate care.
- Health insurance companies — Health insurance companies (health carriers) that must cover certain IVIG treatments under new requirements starting in 2026.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Mandates coverage of IVIG therapy after failed first-line treatments, directly reducing out-of-pocket costs for families of children with PANDAS/PANS—a condition with high treatment costs and limited insurance coverage—potentially preventing hospitalizations and school failure.
HealthcarePeopleRef: Sec. 1(1)Requires subspecialist involvement in treatment decisions, improving diagnostic accuracy and care coordination for a complex neuropsychiatric condition often misdiagnosed or undertreated, especially for vulnerable youth.
HealthcarePeopleRef: Sec. 1(1)(b)By enabling earlier, effective treatment, the bill may reduce long-term educational disruption and special education needs for affected children, improving school attendance and academic outcomes.
EducationPeopleRef: Fiscal Impact sectionExplicitly includes adolescents and allows adult subspecialist consultation for older patients, recognizing the extended age range of PANS/PANDAS and preventing coverage gaps at age 18.
HealthcarePeopleRef: Sec. 1(1)May reduce long-term public costs by improving outcomes and decreasing reliance on emergency psychiatric care, residential treatment, or foster care involvement for youth with untreated PANDAS/PANS.
HealthcarePeopleRef: Fiscal Impact section
Potential Concerns (5)
Requires patients to fail two prior treatments before accessing IVIG, which may delay access to potentially effective care for children with acute, severe psychiatric symptoms, worsening outcomes during critical developmental windows.
HealthcarePeopleRef: Sec. 1(1)(a)Mandates clinical reevaluation every three months to continue coverage, creating administrative burden for families and providers and potentially disrupting continuity of care if reapprovals are delayed or denied.
HealthcarePeopleRef: Sec. 1(2)Requires joint recommendation by a subspecialist and primary care provider, which may limit access in rural or underserved areas where pediatric subspecialists are scarce, even with telehealth allowed.
HealthcareLean peopleRef: Sec. 1(1)(b)The bill does not address funding for implementation, training, or provider capacity expansion—risks of under-resourced rollout could strain emergency mental health systems if patients deteriorate while waiting for coverage approval.
Public SafetyRef: Fiscal Impact sectionHealth insurers may pass administrative costs to employers or through premium adjustments, though the fiscal impact is unspecified and likely modest given the narrow condition and treatment criteria.
Business & EmploymentRef: Fiscal Impact section
Who Is Most Affected
Children and adolescents with PANDAS/PANS stand to gain significant clinical benefit and reduced financial burden, especially those whose families cannot afford out-of-pocket IVIG costs ($15,000–$30,000/year). However, procedural barriers may delay access for those in underserved areas.
Families—especially low- and middle-income—benefit from reduced out-of-pocket costs and improved access to a medically necessary treatment, but may face administrative hurdles and travel/logistical burdens due to subspecialist requirements.
Pediatric subspecialists gain authority in treatment decisions and may see improved diagnostic consistency, but face increased administrative duties (e.g., teleconsultations, reevaluations) and potential capacity strain in shortage areas.
Health insurers face new coverage obligations and administrative costs, but the narrow scope (only IVIG for PANDAS/PANS after failed treatments) limits fiscal impact; large national plans may absorb costs more easily than small regional carriers.